MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Editas Medicine Inc

Open

SectorHealthcare

4.02 9.24

Overview

Share price change

24h

Current

Min

3.61

Max

4.01

Key metrics

By Trading Economics

Income

23M

-53M

Sales

-1.1M

3.6M

Profit margin

-1,487.842

Employees

246

EBITDA

23M

-49M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+9.3% upside

Dividends

By Dow Jones

Next Earnings

3 lis 2025

Market Stats

By TradingEconomics

Market Cap

132M

317M

Previous open

-5.22

Previous close

4.02

News Sentiment

By Acuity

100%

0%

358 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Editas Medicine Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 paź 2025, 23:30 UTC

Hot Stocks

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 paź 2025, 21:21 UTC

Earnings

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 paź 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 paź 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 paź 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 paź 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 paź 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 paź 2025, 22:54 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 paź 2025, 22:54 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 paź 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 paź 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 paź 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 paź 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

2 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 paź 2025, 20:49 UTC

Acquisitions, Mergers, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 paź 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 paź 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 paź 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 paź 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 paź 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 paź 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 paź 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 paź 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Comparison

Price change

Editas Medicine Inc Forecast

Price Target

By TipRanks

9.3% upside

12 Months Forecast

Average 3.88 USD  9.3%

High 6 USD

Low 1 USD

Based on 12 Wall Street analysts offering 12 month price targets forEditas Medicine Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

12 ratings

5

Buy

5

Hold

2

Sell

Technical Score

By Trading Central

1.33 / 1.54Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

No Evidence

Sentiment

By Acuity

358 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat